This study examines the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs in hepatitis C care. Four times as prevalent in the US as HIV infection, hepattis C is already the leading cause of liver failure and liver transplantation, the disease burden and health care costs will continue to rise in the coming decades, and the 1.5-2.0 million people who inject illicit drugs are the most severely affected. If we are to end the hepatitis C epidemic in or country, data are needed on effective methods to provide successful antiviral therapy to the core population affected by the epidemic
Project Investigators
Pedro Mateu-Gelabert PI
Associate Professor of Community Health and Social Sciences
Project Staff
Chunki Fong
Research Scientist